Inhibitors of multidrug resistance transporter P-glycoprotein
The present disclosure provides a method of treating a subject that is resistant to one or more drugs by identifying a subject having one or more drug resistant cells; administering to the subject a pharmaceutically effective amount of an inhibitor compound, and contacting one or more drug resistant cells with the inhibitor compound to reduce the export of the inhibitor compound from the one or more drug resistant tumor cells and to block the transport of drug(s) from the one or more drug resistant cells.
1. A method of treating a subject having cancer that is resistant to one or more chemotherapeutic drugs comprising the steps of:
identifying a subject having one or more drug resistant prostate cancer cells that express a P-glycoprotein;
administering to the subject a pharmaceutically effective amount of an inhibitor compound having one of the following structural formulas:
contacting the one or more drug resistant prostate cancer cells with the inhibitor compound to reduce the drug resistance of the cancer cells.
2. The method of claim 1 , wherein the inhibitor compound interacts with an exporter protein.
3. The method of claim 1 , wherein the inhibitor compound is a P-glycoprotein inhibitor.
4. The method of claim 1 , wherein the inhibitor compound interacts with drug-toxin pumping structures of a P-glycoprotein.
5. The method of claim 1 , wherein the inhibitor compound interacts with ATP binding domain(s) of a P-glycoprotein and the inhibitor compound does not bind to drug binding site(s) on the P-glycoprotein.
6. The method of claim 1 , wherein the inhibitor compound is transported by a P-glycoprotein.
7. The method of claim 1 , wherein the one or more drug resistant cancer cells are one or more multidrug resistant tumor cells.
8. The method of claim 1 , further comprising the step of administering one or more chemotherapeutic agents to the subject.
9. The method of claim 1 , wherein the inhibitor compound is effective for at least one of: increasing the effectiveness of the chemotherapeutic drug to inhibit proliferation, inducing cell death, or indirectly inhibiting development of a tumor by suppressing tumor angiogenesis, reducing the export of the inhibitor compound from the one or more drug resistant tumor cells, to block the transport of chemotherapeutic drug(s) from the one or more drug resistant cancer cells, or increasing an efficacy of one or more chemotherapeutics and/or decreasing toxicity of the chemotherapeutic treatment(s).